The Global Cancer Immunotherapy Market is expected to grow at a CAGR of around 13.22% during the forecast period, i.e., 2021-26, says MarkNtel Advisors in their research report. Cancer immunotherapy has shown an increased survival rate & reduced toxicity. The major factors driving the market are the rising adoption of immunotherapy treatment since it's more effective than conventional methods, coupled with ongoing research & regulatory approvals to meet the mounting requirements of cancer treatment.

According to GLOBOCON, in 2020, the global cancer burden increased to 19.2 million new cases & 9.9 million deaths, which is another crucial aspect likely to fuel the overall market growth in the coming years. The leading market players include AstraZeneca plc, Amgen, Novartis AG, Merck & Co., Inc., Celgene Corporation, Bristol-Myers, Pfizer, Bayer, F. Hoffmann-La-Roche, and Squibb.

The Global Cancer Immunotherapy Market, based on the End-User, bifurcates into:
• Hospitals
• Clinics
• Cancer Research Centers
Of these three, Hospitals accounted for the largest market share in the previous few years, mainly due to the increase in patient footfall in hospitals, mounting facilities within the Ambulatory Surgery Center (ASC) category, and surging use of cancer immunotherapy in hospitals.

For more information visit: https://www.marknteladvisors.com/research-library/global-cancer-immunotherapy-market.html

Depending on patients' conditions, numerous immunotherapy sessions are required in a particular interval. The cost of each session is approximately between ₹1-1.5 lakh and varies as per clinical terms. Hospitals provide cutting-edge treatments, including cancer vaccines, cellular therapies, and other experimental drugs that use patients' immune systems to fight cancer.

On the other hand, based on cancer, Melanoma Cancer is expected to capture a substantial market share in the coming years. Although melanoma accounts for less than 5% percent of all skin cancers, it is still the cause of maximum deaths due to skin cancer.

The immunotherapy drugs commonly used to treat melanoma are called checkpoint inhibitors. They release T cells that identify & destroy cancer cells. For instance, Atezolizumab (Tecentriq) is a drug that targets PD-L1, a protein related to PD-1 found on some tumor cells & immune cells. By blocking this protein, the drug help boosts the immune response against melanoma cells.

According to GLOBOCAN, 324635 people were diagnosed with melanoma cancer, with 57043 reported deaths, in 2020. Further, the number of cases expected to occur in the next five years will be approximately 1092818. Hence, the increasing burden of melanoma cancer is projected to fuel the demand for cancer immunotherapy in the years to come.

Key Questions Answered in the Study
1. What are the current & future trends in the Global Cancer Immunotherapy Market?
2. How has the industry been evolving in terms of geography & service adoption?
3. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
4. What are the key growth drivers & challenges for the Global Cancer Immunotherapy Market?
5. What are the customer orientation, purchase behavior, and expectations from Cancer Immunotherapy providers across the globe?

Market Segmentation:
1. By Product Type (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies & Cancer Vaccines, Checkpoint Inhibitors)
2. By Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head & Neck Cancer, Melanoma, Colorectal Cancer)
3. By End-User (Hospitals, Clinics and Cancer Research Centers)
4. By Region (North America, Latin America, Europe, Middle East & Africa, Asia-Pacific)
5. By Country (United States, Canada, Mexico, Brazil, Argentina, Germany, Italy, United Kingdom, Spain, France, Saudi Arabia, UAE, Turkey, South Africa, China, India, Japan, Australia, South Korea)
6. By Company (AstraZeneca plc, Amgen, Novartis AG, Merck & Co., Inc., Celgene Corporation, Bristol-Myers, Pfizer, Bayer, F. Hoffmann-La-Roche, Squibb)